SCHEMBL16201382

SCHEMBL16201382

CCCN(C)Cc1c[nH]nc1-c1cccc(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK14 Q16539 3/20 0.39
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
PRMT6 Q96LA8 2/20 0.37
PRMT8 Q9NR22 2/20 0.37
POLB P06746 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
PRMT3 O60678 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT1 Q99873 1/20 0.35
LMNA P02545 1/20 0.35
IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16125821 0.89 PRMT6 (0.48) SMN1; SMN2L3MBTL1MAPK14MAPTNPSR1
SCHEMBL16201373 0.86 STK4 (0.44) MEN1KMT2APRMT6PRMT8POLB
SCHEMBL16201329 0.86 NPC1 (0.44) MAPTNPSR1KDM4EMEN1GAA
SCHEMBL16201410 0.86 NOTUM (0.38) SMN1; SMN2MAPTKDM4EPRMT6PRMT8
SCHEMBL16201341 0.85 MOK (0.37) MAPK14KMT2APRMT6PRMT8PRMT3
SCHEMBL16201387 0.85 GAA (0.41) MAPTNPSR1KDM4EMEN1GAA
SCHEMBL16201421 0.84 MEN1 (0.36) SMN1; SMN2L3MBTL1MAPTNPSR1KDM4E
SCHEMBL16201334 0.83 LRRK2 (0.40) MEN1KMT2ALMNAIDO1CYP2C9
SCHEMBL16201368 0.82 CARM1 (0.38) MAPTPRMT6PRMT8PRMT3CARM1
SCHEMBL16201446 0.82 PRMT6 (0.42) PRMT6PRMT8PRMT3CARM1PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 SMN1; SMN2 1252/4885L3MBTL1 541/4885MAPK14 2928/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 SMN1; SMN2 2641/4885L3MBTL1 1016/4885MAPK14 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.